Figure 1.

Clinical course and mutations detected in I-2(a) and II-1(b). Germline mutation in DNMT3A P709S (black) and predominant somatic mutations in IDH2 R172K and ASXL1 P808fs (grey) that were detected within bone marrow samples at various timepoints (blue) along with the regimens and protocols given (green): CIA (induction of clofarabine, idarubicin and cytarabine), SGI-110 (DNMT inhibitor), BL-8040 (CXCR4 inhibitor), TH302 (Evofosfamide, replication inhibitor), AZD1208 (Pim-kinase inhibitor), Erlotinib (epidermal growth factor receptor (EGFR) inhibitor), PRI-724 (Wnt inhibitor), J0894 + J9100 (Decitabine + Cytarabine), AG221 x 2 cycles (IDH2 inhibitor), Trametinib (MEK inhibitor), APTO-253 (MTF-1 inhibitor) are shown